Somewhat Favorable News Coverage Somewhat Unlikely to Impact Biogen (BIIB) Stock Price
Headlines about Biogen (NASDAQ:BIIB) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biogen earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.5777086891957 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- Biogen (BIIB) vs. Peregrine Pharmaceuticals (PPHM) Head-To-Head Review (americanbankingnews.com)
- Vetr Inc. Downgrades Biogen Inc. (BIIB) to Hold (americanbankingnews.com)
- Biogen Inc. (BIIB) Cut to “Hold” at ValuEngine (americanbankingnews.com)
- Biogen Inc. (BIIB) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Why this stock is considered to be Overbought? Biogen Inc. (BIIB … – Voice Of Analysts (analystsbuzz.com)
A number of research analysts have commented on the stock. UBS Group AG raised shares of Biogen from a “sell” rating to a “neutral” rating and upped their target price for the company from $262.00 to $270.00 in a research report on Monday, June 19th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $307.00 target price on shares of Biogen in a research report on Wednesday, June 14th. Leerink Swann reaffirmed a “market perform” rating and issued a $338.00 target price (up previously from $304.00) on shares of Biogen in a research report on Wednesday, July 26th. Vetr cut shares of Biogen from a “buy” rating to a “hold” rating and set a $298.30 target price on the stock. in a research report on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) raised shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 target price on the stock in a research report on Wednesday, August 16th. Thirteen investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $328.70.
Shares of Biogen (NASDAQ:BIIB) traded up 1.41% during trading on Monday, reaching $321.01. 2,083,874 shares of the company’s stock traded hands. Biogen has a 1-year low of $244.28 and a 1-year high of $322.12. The stock has a market capitalization of $67.87 billion, a PE ratio of 21.07 and a beta of 0.77. The company has a 50 day moving average price of $288.68 and a 200 day moving average price of $276.07.
Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.36 by $0.68. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period in the prior year, the company posted $5.21 EPS. Biogen’s quarterly revenue was up 6.4% on a year-over-year basis. On average, equities analysts forecast that Biogen will post $21.44 EPS for the current fiscal year.
In other news, EVP Susan H. Alexander sold 4,974 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total value of $1,442,509.74. Following the completion of the sale, the executive vice president now directly owns 22,258 shares in the company, valued at approximately $6,455,042.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brian S. Posner sold 1,084 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $256.31, for a total value of $277,840.04. Following the completion of the sale, the director now owns 6,330 shares of the company’s stock, valued at $1,622,442.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,816 shares of company stock worth $3,931,380. 0.32% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/04/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-biogen-biib-stock-price.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.